摘要第8版国际抗癌联盟(UICC)和美国癌症联合委员会(AJCC)(UICC/AJCC)2017年公布的食管癌新分期着重关注了食管癌治疗前分期准确性和淋巴结转移的预后意义、早期肿瘤治疗合理性和诱导治疗的重要性,在此基础上修改的2017版美国国立综合癌症网络(NCCN)指南配合食管癌UICC/AJCC第8版新分期,加入了术前临床分期指导治疗选择的内容,重新定义了早期食管鳞癌的内镜切除适应证和手术指征,并再次强调术前诱导治疗对于局部进展期食管鳞癌的重要意义.虽然还有很多悬而未决的问题需要进一步探讨,但理解食管癌的发展规律和预后相关因素,从解决实际问题出发开展针对性研究,强调规范化诊治是提高食管癌疗效的基本策略.

abstractsThe eighth edition of Union for International Cancer Control (UICC)and the American Joint Committee on Cancer(AJCC)announced in 2017 the new staging of esophageal cancer, focusing on the prognostic significance of accurate staging and lymph node metastasis before treatment of esophageal carcinoma, the rationality of early tumor therapy, and the importance of induction therapy. The modified 2017 edition of the National Comprehensive Cancer Network (NCCN)guidelines, based on above contents matching UICC/AJCC eighth edition of the new staging of esophageal cancer, added preoperative clinical staging to guide the selection of treatment, and re-defined the indications of endoscopic resection and operation for early esophageal squamous cell carcinoma, meanwhile emphasized once again the importance of preoperative induction therapy for locally advanced esophageal squamous cell carcinoma. While there are still many pendent problems that need to be explored further, the knowledge of the law of progression in esophageal cancer and the factors related to prognosis, launching targeted researches for solving practical problems, and the emphasis of standardized diagnosis and treatment are the basic strategies to improve the efficacy of esophageal carcinoma.